FDA approves Keytruda as adjuvant treatment for kidney cancer
The cancer immunotherapy drug Keytruda (pembrolizumab), was approved Thursday by the U.S. Food and Drug Administration (FDA) to help in the fight against renal cell carcinoma (RCC), according…